GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » EV-to-EBITDA

Lumos Diagnostics Holdings (ASX:LDX) EV-to-EBITDA : -7.11 (As of May. 31, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lumos Diagnostics Holdings's enterprise value is A$24.50 Mil. Lumos Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-3.45 Mil. Therefore, Lumos Diagnostics Holdings's EV-to-EBITDA for today is -7.11.

The historical rank and industry rank for Lumos Diagnostics Holdings's EV-to-EBITDA or its related term are showing as below:

ASX:LDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.32   Med: -2.35   Max: -0.01
Current: -7.11

During the past 3 years, the highest EV-to-EBITDA of Lumos Diagnostics Holdings was -0.01. The lowest was -7.32. And the median was -2.35.

ASX:LDX's EV-to-EBITDA is ranked worse than
100% of 494 companies
in the Medical Devices & Instruments industry
Industry Median: 15.78 vs ASX:LDX: -7.11

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Lumos Diagnostics Holdings's stock price is A$0.028. Lumos Diagnostics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.013. Therefore, Lumos Diagnostics Holdings's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Lumos Diagnostics Holdings EV-to-EBITDA Historical Data

The historical data trend for Lumos Diagnostics Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings EV-to-EBITDA Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
EV-to-EBITDA
-0.46 -1.84 -2.11

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial - -1.84 - -2.11 -

Competitive Comparison of Lumos Diagnostics Holdings's EV-to-EBITDA

For the Medical Devices subindustry, Lumos Diagnostics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Diagnostics Holdings's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's EV-to-EBITDA falls into.


;
;

Lumos Diagnostics Holdings EV-to-EBITDA Calculation

Lumos Diagnostics Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=24.500/-3.448
=-7.11

Lumos Diagnostics Holdings's current Enterprise Value is A$24.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumos Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-3.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Diagnostics Holdings  (ASX:LDX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Lumos Diagnostics Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.028/-0.013
=At Loss

Lumos Diagnostics Holdings's share price for today is A$0.028.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumos Diagnostics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Lumos Diagnostics Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Diagnostics Holdings Business Description

Traded in Other Exchanges
Address
2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

No Headlines